Pipeline Overview

Our Development Programs

Program (click indication for details)
Phase 1
Phase 2
Phase 3
NDA / MAA Approved

ADASUVE®: Staccato loxapine

To see full prescribing information, including boxed warning, visit www.ADASUVE.com or the EMA website

AZ-002: Staccato alprazolam

For more information, visit www.EngageTherapeutics.com

AZ-003: Staccato FENTANYL

Cancer breakthrough pain.

AZ-007: Staccato zaleplon

Middle of the night awakening.

To discuss partnership and licensing opportunities,
please contact our Business Development Group.

Corporate Headquarters
2091 Stierlin Court
Mountain View, CA 94043
TEL: 650 944 7000
FAX: 650 944 7999
Email Us
Back to top